Cargando…

Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer

INTRODUCTION: It is widely believed that discovery of specific, sensitive, and reliable tumor biomarkers can improve the treatment of cancer. Currently, there are no obvious targets that can be used in treating triple-negative breast cancer (TNBC). METHODS: To better understand TNBC and find potenti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Ming, Whelan, Stephen A., He, Jianbo, Saxton, Romaine E., Faull, Kym F., Whitelegge, Julian P., Chang, Helena R.
Formato:	Texto
Lenguaje:	English
Publicado:	Humana Press Inc 2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2937135/ https://www.ncbi.nlm.nih.gov/pubmed/20930921 http://dx.doi.org/10.1007/s12014-010-9052-1

Ejemplares similares

Proteomics and Mass Spectrometry for Cancer Biomarker Discovery
por: Lu, Ming, et al.
Publicado: (2007)

Proteomic-Based Biosignatures in Breast Cancer Classification and Prediction of Therapeutic Response
por: He, Jianbo, et al.
Publicado: (2011)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
por: Vos, Hanne, et al.
Publicado: (2021)

Combined Phosphoproteomics and Bioinformatics Strategy in Deciphering Drug Resistant Related Pathways in Triple Negative Breast Cancer
por: Deng, Xinyu, et al.
Publicado: (2014)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

Targeting a Subset of the Membrane Proteome for Top–Down Mass Spectrometry: Introducing the Proteolipidome
por: Whitelegge, Julian
Publicado: (2020)

Reversal of HER2 Negativity: An Unexpected Role for Lovastatin in Triple-Negative Breast Cancer Stem Cells
por: Yi, Huimei, et al.
Publicado: (2020)

Functional Proteomic Profiling of Triple-Negative Breast Cancer
por: Gromova, Irina, et al.
Publicado: (2021)

Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment
por: Onesti, Concetta Elisa, et al.
Publicado: (2018)

Extracellular Vesicles From Auditory Cells as Nanocarriers for Anti-inflammatory Drugs and Pro-resolving Mediators
por: Kalinec, Gilda M., et al.
Publicado: (2019)

Carcinogenesis of Triple-Negative Breast Cancer and Sex Steroid Hormones
por: Honma, Naoko, et al.
Publicado: (2021)

The Potential of Hormonal Therapies for Treatment of Triple-Negative Breast Cancer
por: Kirkby, Melanie, et al.
Publicado: (2023)

Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
por: Li, Jie, et al.
Publicado: (2020)

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
por: Bartsch, Rupert
Publicado: (2021)

De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer
por: Tasoulis, Marios-Konstantinos, et al.
Publicado: (2022)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
por: Xun, Xueqiong, et al.
Publicado: (2023)

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients
por: Machleidt, Anna, et al.
Publicado: (2013)

Identities of Sequestered Proteins in Aggregates from Cells with Induced Polyglutamine Expression
por: Suhr, Steven T., et al.
Publicado: (2001)

Comparison of Clinico-Pathological Presentations of Triple-Negative versus Triple-Positive and HER2 Iraqi Breast Cancer Patients
por: Alwan, Nada A. S., et al.
Publicado: (2019)

A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer
por: Yau, Christina, et al.
Publicado: (2010)

Roles of MALAT1 in development and migration of triple negative and Her-2 positive breast cancer
por: Xiping, Zhang, et al.
Publicado: (2017)

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients
por: Lefort, S, et al.
Publicado: (2017)

Varlitinib Downregulates HER/ERK Signaling and Induces Apoptosis in Triple Negative Breast Cancer Cells
por: Liu, Chun-Yu, et al.
Publicado: (2019)

Molecular Mechanisms Associated with Brain Metastases in HER2-Positive and Triple Negative Breast Cancers
por: Bryan, Sarah, et al.
Publicado: (2021)

Identification of Differentially Expressed Proteins in Murine Embryonic and Postnatal Cortical Neural Progenitors
por: Shoemaker, Lorelei D., et al.
Publicado: (2010)

Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples
por: Ho-Pun-Cheung, Alexandre, et al.
Publicado: (2019)

Management Options in Triple-Negative Breast Cancer
por: Minami, Christina A., et al.
Publicado: (2011)

Interplay between Epigenetics, Expression of Estrogen Receptor- α, HER2/ERBB2 and Sensitivity of Triple Negative Breast Cancer Cells to Hormonal Therapy
por: Ramadan, Wafaa S, et al.
Publicado: (2018)

EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer
por: Almstedt, K., et al.
Publicado: (2020)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Recent advances of transcriptomics and proteomics in triple‐negative breast cancer prognosis assessment
por: Li, Yuan, et al.
Publicado: (2022)

Depletion of Mdig Changes Proteomic Profiling in Triple Negative Breast Cancer Cells
por: Thakur, Chitra, et al.
Publicado: (2022)

High-precision mass measurement of exotic nuclei with the triple-trap mass spectrometer ISOLTRAP
por: Blaum, K, et al.
Publicado: (2003)

High-precision mass measurements of exotic nuclei with the triple-trap mass spectrometer ISOLTRAP
por: Blaum, K, et al.
Publicado: (2002)

High-Precision Mass Measurements of Exotic Nuclei With The Triple-Trap Mass Spectrometer ISOLTRAP
por: Blaum, K, et al.
Publicado: (2006)

High-precision mass measurements of exotic nuclei with the triple-trap mass spectrometer ISOLTRAP
por: Herlert, Alexander, et al.
Publicado: (2006)

High-precision mass measurements of exotic nuclei with the triple-trap mass spectrometer ISOLTRAP
por: CERN. Geneva, et al.
Publicado: (2008)

An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk
por: Yau, Christina, et al.
Publicado: (2013)

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
por: Qiu, Jingdan, et al.
Publicado: (2016)

The Triple Axis and SPINS Spectrometers
por: Trevino, S. F.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_ipq0kfr002rkn2nq8nr78g8n88